Shattuck Strikes Joint Development Deal With Japan's Ono Pharma
By Rob Curran
Shattuck Labs struck a joint-venture deal with Japanese drugmaker Ono Pharmaceutical to develop treatments for autoimmune and inflammatory diseases.
Shattuck, an Austin biotech concern with a laboratory in North Carolina, will receive an undisclosed up-front payment and be eligible for licensing, regulatory, and commercial milestone payments of up to $227 million, and further tiered sales-based royalties.
Under the deal, Shattuck will lead research on certain compounds directed toward targets selected by Ono from Shattuck's pipeline of bifunctional fusion proteins. Shattuck's line of product candidates are intended to treat autoimmune diseases and cancer.
Ono will pay Shattuck's research and development expenses. Shattuck's R&D expenses totaled $59.1 million in the first nine months of 2023.
Ono would later have an option to conduct further research and commercialization worldwide.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
February 13, 2024 06:42 ET (11:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks